Results 91 to 100 of about 5,337 (191)

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract The recent publication of extension data from post‐regulatory trials of amyloid‐lowering antibody therapies, such as donanemab and lecanemab, requires clinicians to critically appraise trial designs and analyses in order to evaluate claims made by authors and sponsors of disease modification.
Jemma Hazan, Kathy Y. Liu, Robert Howard
wiley   +1 more source

Analytical framing of Amyloid beta monoclonal antibody trials in Alzheimer's disease can obscure clinical effects

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract Cochrane Reviews are widely regarded as the gold standard for evidence synthesis, yet analytical framing influences interpretation. A recent Cochrane review of amyloid beta–targeting monoclonal antibodies pools mechanistically and biologically heterogenous interventions.
Betty M. Tijms, Argonde C. van Harten, Maria C. Carillo, Philip Scheltens, Everard G. B. Vijverberg   +4 more
wiley   +1 more source

Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodies

eLife
A hallmark of Alzheimer’s disease (AD), the most common form of dementia, is the progressive accumulation of amyloid-beta (Aβ) peptides across distinct brain regions.
Ivan Talucci, Timon Leske, Hans-Wolfgang Klafki, Mohammed Mehedi Hassan, Annik Steiert, Barbara Morgado, Sebastian Bothe, Lars van Werven, Thomas Liepold, Jochen Walter, Hermann Schindelin, Jens Wiltfang, Oliver Wirths, Olaf Jahn, Hans Michael Maric   +14 more
doaj   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, Volume 46, Issue 4, Page 1173-1229, July 2026.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

ICARE AD‐US: Design of a prospective, single‐arm, multicenter, noninterventional real‐world study of aducanumab in the United States

, 2021
Background Aducanumab is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, and, at the writing of this , is currently under review by the US Food and Drug ...
Porter, Verna R., Mihaela Levitchi Benea, James E. Galvin, Atri, Alireza, Galvin, James E., Verna R. Porter, Carl de Moor, McEwen, Sarah C., Alireza Atri, Ivana Rubino, Benea, Mihaela Levitchi, de Moor, Carl, Rubino, Ivana, Sarah C. McEwen, Cummings, Jeffrey L., Jeffrey L. Cummings   +15 more
core   +1 more source

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve

Biomedicines
Background: Monoclonal antibodies approved by the FDA, lecanemab, donanemab, and aducanumab, are failing to meet the expected efficacy to treat early Alzheimer’s disease, and aducanumab has been recalled.
Sarfaraz K. Niazi
doaj   +1 more source

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

, 2017
This corrects the article DOI: 10.1038/nature21361. Erratum for An intermediate-mass black hole in the centre of the globular cluster 47 Tucanae. [Nature. 2017] The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Grimm, Jan, Nitsch, Roger M, Sandrock, Alfred, et al, Hock, Christoph, Sevigny, Jeff, Chiao, Ping   +6 more
core   +1 more source

A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundAlzheimer’s disease poses a major public health challenge, with aducanumab’s approval in 2021 as the first disease-modifying therapy raising important safety considerations.
Jingjing Huang, Xiaohong Long, Chunyong Chen   +2 more
doaj   +1 more source

Fit for purpose high‐throughput absolute quantitation of chimeric aducanumab in mouse cortex and plasma [PDF]

Background: Although pharmacokinetics and pharmacodynamics of biotherapeutics are commonly studied through ELISAs; however, the extremely strong binding of modern antibody‐based therapeutics result in background, inability of secondary antibody binding ...
Haynes, Kathryn A., Doud, Emma H., Quinney, Sara K., Mosley, Amber L., Silva Santos, Diogo Francisco, Sukoff Rizzo, Stacey J., Territo, Paul R.   +6 more
core   +1 more source

Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review

Journal of Education, Health and Sport
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for ...
Agnieszka Skoczeń, Natalia Rutecka, Błażej Kaczmarek, Agata Kuśnierz-Gibała, Adrian Kruk, Michał Kulesza, Weronika Wawrzynów, Martyna Miłoś, Aleksandra Dorosz, Magdalena Maria Jakubowska   +9 more
doaj   +1 more source